Amazon Backed Anthropic Unveils Hybrid AI Model with Reasoning Ability
Anthropic, the AI startup backed by Amazon, has unveiled a new hybrid AI model that combines fast response and deep reasoning capabilities. This model, which uses a token-based sliding scale to control computational resources, is designed to provide users with the best balance between speed, performance, and cost.
The hybrid AI model, which Anthropic plans to release in the coming weeks, outperforms OpenAI's GPT-3Mini-high on certain programming tasks and demonstrates a stronger understanding and reasoning capability when handling complex business codebases. This model is expected to give customers more control over how long it takes to reason to solve a query, with developers able to adjust the tokens using a 'liding scale'.
Anthropic's new model is part of the company's broader strategy to grow its product offerings and support businesses that will responsibly deploy Claude in the market. The company is also working on new features such as 100K context windows, which will allow users to submit hundreds of pages of materials for Claude to digest and analyze.
In connection with the new model, Anthropic has announced that Yasmin Razavi, a General Partner at Spark Capital focused on growth stage software investments, has joined Anthropic's Board of Directors. Razavi said, "All of us at Spark are excited to partner with Dario, Daniela, and the entire Anthropic team on their mission to build reliable and honest AI systems. Anthropic has assembled a world-class technical team that is dedicated to building safe and capable AI systems. The overwhelmingly positive response to Anthropic’s products and research hints at AI’s broader potential for unlocking a new paradigm of flourishing in our society."
Anthropic's new hybrid AI model is expected to bring a new competitive landscape to the AI field and provide developers with more diverse choices. The model's features balancing speed, deep reasoning, and cost control are expected to show strong competitiveness in practical applications. This new model is certainly worth looking forward to!

Name |
---|
Date |
Basic EPS(USD) |
Average Price Target(USD) |
Total Revenue YoY% |
R&D Expenses(USD) |
ROE(Average)% |
AN2 TherapeuticsANTX |
20240930 |
-0.43 |
-- |
-- |
8.29M |
-41.25 |